证券代码：301363 证券简称：美好医疗 公告编号：2026-002 深圳市美好创亿医疗科技股份有限公司 关于实际控制人一致行动人、董事及高管减持股份预披露公告 深圳市美泰联实业有限公司、深圳市美创联合投资合伙企业（有限合伙）、 深圳市美创银泰实业合伙企业（有限合伙）、深圳市美创金达投资合伙企业（有 限合伙）、董事 JOEL CHAN、副总经理严俊峨、黄凯、严波保证信息披露内容 的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 特别提示： 1、持有深圳市美好创亿医疗科技股份有限公司（以下简称"公司"或"本公司"） 股份43,400,000股（占公司总股本的比例为7.6291%）的股东深圳市美泰联实业有限 公司（以下简称为"美泰联"）、持有本公司股份41,230,000股（占公司总股本的比例 为7.2477%）的股东深圳市美创联合投资合伙企业（有限合伙）（以下简称为"美创 联合"）、持有本公司股份36,022,000股（占公司总股本的比例为6.3322%）的股东深 圳市美创银泰实业合伙企业（有限合伙）（以下简称为"美创银泰"），以及 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights the ongoing performance of the pharmaceutical sector, with a focus on the upcoming annual earnings forecasts and the potential for exceeding expectations. The sector has shown a return of 7.08% since the beginning of 2026, outperforming the CSI 300 index by 4.88% [8][12]. - Key catalysts in the industry include significant partnerships and acquisitions, such as AbbVie’s $6.5 billion upfront payment for RC148 and a $1 billion collaboration between Eli Lilly and NVIDIA to accelerate AI drug development [4][10]. - The report emphasizes the importance of innovative drug chains and the AI+ theme, suggesting that these areas will continue to attract investment and yield positive results [4][5]. Summary by Sections Industry Overview - The pharmaceutical sector's total market capitalization is approximately 74,744.70 billion yuan, with a circulating market value of 68,522.64 billion yuan [2]. - The report notes that the pharmaceutical sector is currently valued at 23.4 times PE based on 2026 earnings forecasts, which is a premium of 13.7% compared to the overall A-share market [15]. Market Dynamics - The report indicates that the pharmaceutical sector has experienced a mixed performance, with medical services up by 3.29% while other segments like medical devices and traditional Chinese medicine have seen declines [8][12]. - The report also mentions that the market is transitioning to a more rational and steady growth phase, moving away from the initial volatility seen at the start of the year [4]. Key Company Performances - Notable companies such as WuXi Biologics, Sangamo Therapeutics, and Tigermed have been highlighted for their strong performance, with WuXi Biologics showing a significant increase of 26.53% in January [24]. - The report suggests continued monitoring of companies involved in AI and small nucleic acid technologies, as they are expected to lead future growth in the sector [5][9]. Investment Recommendations - The report recommends focusing on companies that are well-positioned within the innovative drug chain and AI+ sectors, as these are anticipated to provide substantial returns [4][5]. - Specific stocks recommended include WuXi Biologics, Sangamo Therapeutics, and Tigermed, which have shown promising growth trajectories [24].

Core Viewpoint - The brain-computer interface (BCI) sector in the A-share market has shown significant activity at the beginning of 2026, with a cumulative increase of 18.04% in the BCI theme index as of January 16, 2026, indicating a strong interest and potential for commercialization in this emerging industry [2][4]. Industry Overview - The BCI industry is projected to reach a market size of trillions, transitioning from laboratory research to commercial applications, driven by advancements in technology and supportive government policies [3]. - The Ministry of Industry and Information Technology and other departments have emphasized the importance of BCI in their strategic plans, including its inclusion in the "14th Five-Year Plan" for future industrial development [3]. Market Performance - As of January 16, 2026, the total market capitalization of 26 listed companies in the BCI sector has increased by approximately 108.7 billion yuan over ten trading days [8]. - Notable companies like Innovation Medical and Meihua Medical have experienced significant stock price fluctuations, reflecting the volatile nature of the market and investor sentiment towards BCI technologies [5][7]. Company Developments - Innovation Medical's subsidiary, Boling Brain Machine Technology, has launched products aimed at rehabilitation for stroke patients, although it reported operating losses of 6.6 million yuan and 8.66 million yuan in 2023 and 2024, respectively [6]. - Meihua Medical, a leader in cochlear implants, is actively collaborating with BCI clients to facilitate the transition from laboratory research to commercial production, highlighting the interconnectedness of BCI and existing medical technologies [7]. Strategic Collaborations - Companies like Yahui Long and Shenzhen Brain Machine Star Chain Technology have entered strategic partnerships to develop BCI-related products, aiming to enhance diagnostic and treatment capabilities in central nervous system diseases [9]. - Aipeng Medical is also expanding its business into BCI applications, focusing on pain management and sleep disorders, indicating a broader trend of diversification within the medical device sector [9]. Technical Insights - The core technological barriers in the BCI industry are concentrated in the upstream supply chain, including hardware components and surgical techniques, with significant potential for growth in domestic market penetration and localization [10].

Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].

Group 1 - The construction of a "super factory" by Brain Tiger Technology in Jiangxi marks a significant transition from laboratory research to large-scale production in the brain-computer interface (BCI) sector, aiming for stable supply of tens of thousands of units [1][6] - The factory will produce China's first and the world's second fully implanted, fully wireless, and fully functional BCI system, highlighting the growing market potential across healthcare, consumer electronics, and military applications [1][6] - Global developments include Neuralink's announcement to start large-scale production of BCI devices by 2026, indicating a shift from clinical validation to industrialization [1][6] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document aiming for breakthroughs in key technologies by 2027 and a robust industry system by 2030 [2][7] - The "14th Five-Year Plan" identifies BCI as a future industry requiring strategic development, with various regions setting clear goals for BCI technology and product applications [2][7] - Successful surgeries have been performed on high-level paraplegics using BCI technology, enabling patients to control devices and participate in rehabilitation and employment activities [2][7] Group 3 - The BCI sector has attracted significant investment, with the A-share market showing a cumulative increase of over 20% since 2026, and several stocks rising more than 50% [3][8] - As of January 13, 2023, the financing balance for 26 BCI-related stocks reached nearly 25.5 billion yuan, a 15% increase from the previous year, with many stocks seeing substantial increases in their financing [3][8] - Notable companies include Meihua Medical, with a financing balance of 470 million yuan and a 255% increase, and Innovation Medical, with a balance of 744 million yuan and a 105% increase [3][8][9]

Group 1 - The core point of the article highlights the significant advancements in the brain-computer interface (BCI) industry, particularly with the construction of Brain Tiger Technology's "super factory" in Jiangxi, which marks a transition from laboratory research to large-scale production of BCI systems [3] - The factory aims to produce the first domestically developed and the world's second fully implanted, wireless, and fully functional BCI system, targeting stable supply of tens of thousands of units [3] - The BCI technology shows immense potential across various sectors, including healthcare, consumer electronics, and military aerospace, with significant developments occurring globally [3] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document issued in July 2025 outlining goals for technological breakthroughs and the establishment of a robust industry framework by 2030 [4] - The market for BCIs is projected to grow significantly, with global market size expected to reach approximately $2.62 billion in 2024 and $12.4 billion by 2034, while China's market is anticipated to grow from 3.2 billion yuan in 2024 to 5.58 billion yuan by 2027, reflecting a compound annual growth rate of about 20% [4] Group 3 - The BCI sector has attracted substantial investment, with the A-share market seeing a cumulative increase of over 20% in the BCI theme index since 2026, and several stocks experiencing gains exceeding 50% [5] - As of January 13, 2023, 19 out of 26 BCI concept stocks were eligible for margin trading, with a total financing balance of nearly 25.5 billion yuan, an increase of over 15% compared to the end of the previous year [5] - Notable companies such as Meihua Medical and Innovation Medical have seen significant increases in their financing balances, indicating strong investor interest and strategic partnerships in the BCI field [5][6]

Group 1 - The core point of the article is that Meihao Medical (301363) reported a total of 42,300 shareholders as of January 9, 2026 [1]

Core Viewpoint - The company, Meihao Medical, is a leading player in the cochlear implant market and is actively involved in the development of brain-machine interface (BMI) technologies, highlighting the potential for long-term applications in clinical settings [1] Group 1: Company Overview - Meihao Medical is recognized as a strategic partner and core supplier in the global cochlear implant industry, with nearly 15 years of deep collaboration with clients in the development and production of cochlear implant components [1] - The company emphasizes that cochlear implants are a successful example of current clinical applications and have a design lifespan that supports long-term or even lifetime use [1] Group 2: Industry Insights - The invasive brain-machine interface products share significant technological similarities with cochlear implants, particularly in areas such as material selection, biocompatibility requirements, production processes, and quality system control [1] - The company is engaged in in-depth process exploration and technical cooperation with innovative BMI clients, assisting them in transitioning from laboratory research to efficient commercial production [1] - Currently, the revenue generated from the company's brain-machine interface business is relatively small, indicating potential growth opportunities in this emerging sector [1]

证券日报网讯 1月14日，美好医疗在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东 总户数为14691户。 （文章来源：证券日报） ...

此次政策调整后，这部分增量资金将有所减少，对高波动板块如热门题材、小盘股等可能形成短期的资金面压制，面临一定的回调压力。对于依 赖融资资金推动股价的高融资个股而言，保证金比例上调后，新增融资的杠杆倍数从1.25倍降至1倍，投资者需投入更多自有资金才能获得相同 规模的融资额度。 根据Choice数据显示，近1个月融资余额增长在100%以上的高融资个股共有48只(剔除北交所个股)，近1个月融资余额增幅位居前三的分别是星 环科技-U、邵阳液压、美好医疗，同时也包括商业航天热门股：航天动力、金风科技等。另外，在近3个月行情中融资余额环比减少20%以上的 也有85只个股。 （ 点此领取名单 ） 本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 今日午间，沪深北三大交易所同步发布通知，宣布经中国证监会批准，将投资者融资买入证券时的融资保证金最低比例从现行的80%上调至 100%。意味着投资者进行融资交易时需要缴纳更多的自有资金作为保证金。 截至2026年1月13日，A股两融余额已达到2.67万亿元，创下历史新高，相比2024年年末的18541亿元，增加超8000亿元，是市场主要的增量资 金之一；2026年开 ...